Premium
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
Author(s) -
Breccia M.,
Carmosino I.,
Russo E.,
Morano S. G.,
Latagliata R.,
Alimena G.
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00351.x
Subject(s) - medicine , nausea , imatinib , chronic myeloid leukaemia , vomiting , adverse effect , dermatology , myeloid leukemia , rash , gastroenterology
Imatinib related non‐haematological side‐effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well‐recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.